Trial Profile
A phase II study of temozolomide (Temodar) in the treatment of adult patients with supratentorial low grade glioma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 28 May 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.